CompletedPhase 2NCT00666588
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
Studying Acute basophilic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Jeffrey Moscow, D.CChildren's Oncology Group
- Intervention
- idarubicin(drug)
- Enrollment
- 52 enrolled
- Eligibility
- 1-21 years · All sexes
- Timeline
- 2008 – 2012
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Southern California Permanente Medical Group, Downey, California, United States
- Miller Children's Hospital, Long Beach, California, United States
- Children's Hospital and Research Center at Oakland, Oakland, California, United States
- Childrens Hospital of Orange County, Orange, California, United States
- Packard Children's Hospital Stanford University, Palo Alto, California, United States
- University of California San Francisco Medical Center, San Francisco, California, United States
- Connecticut Children's Medical Center, Hartford, Connecticut, United States
- Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Broward General Medical Center, Fort Lauderdale, Florida, United States
- Lee Memorial Health System, Fort Myers, Florida, United States
- Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00666588 on ClinicalTrials.govOther trials for Acute basophilic leukemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT01627041Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT00898456Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaAlliance for Clinical Trials in Oncology